Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alvocidib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 known ✓ | P24941 | 14/20 | 0.98 |
| ▸ | CDK4 known ✓ | P11802 | 12/20 | 0.98 |
| ▸ | CDK1 known ✓ | P06493 | 11/20 | 0.98 |
| ▸ | CDK9 known ✓ | P50750 | 11/20 | 0.98 |
| ▸ | CDK7 known ✓ | P50613 | 3/20 | 0.98 |
| ▸ | CDK6 known ✓ | Q00534 | 2/20 | 0.98 |
| ▸ | CCND1 | P24385 | 10/20 | 0.98 |
| ▸ | CCNT1 | O60563 | 9/20 | 0.98 |
| ▸ | CCNB1 | P14635 | 8/20 | 0.98 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.98 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.98 |
| ▸ | CCNB2 | O95067 | 5/20 | 0.98 |
| ▸ | CCNB3 | Q8WWL7 | 5/20 | 0.98 |
| ▸ | GSK3B | P49841 | 4/20 | 0.98 |
| ▸ | GSK3A | P49840 | 4/20 | 0.98 |
| ▸ | CCNE2 | O96020 | 4/20 | 0.98 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.98 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.98 |
| ▸ | CAMK2G | Q13555 | 3/20 | 0.98 |
| ▸ | CDK12 | Q9NYV4 | 3/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alvocidib SCHEMBL30848987 | 1.00 | CDK2 (0.98) | CDK2CDK4CDK1CDK9CCND1 | |
| Alvocidib SCHEMBL29772535 | 1.00 | CDK2 (0.98) | CDK2CDK4CDK1CDK9CCND1 | |
| Alvocidib SCHEMBL1170833 | 1.00 | CDK2 (0.98) | CDK2CDK4CDK1CDK9CCND1 | |
| Alvocidib SCHEMBL1181340 | 1.00 | CDK2 (0.98) | CDK2CDK4CDK1CDK9CCND1 | |
| Alvocidib SCHEMBL12445809 | 0.99 | CDK2 (1.00) | CDK2CDK4CDK1CDK9CCND1 | |
| Alvocidib SCHEMBL16927354 | 0.99 | CDK2 (1.00) | CDK2CDK4CDK1CDK9CCND1 | |
| Flavopyridol SCHEMBL22580715 | 0.99 | CDK2 (1.00) | CDK2CDK4CDK1CDK9CCND1 | |
| Alvocidib SCHEMBL3651 | 0.99 | CDK2 (1.00) | CDK2CDK4CDK1CDK9CCND1 | |
| Alvocidib SCHEMBL8214028 | 0.99 | CDK2 (1.00) | CDK2CDK4CDK1CDK9CCND1 | |
| Alvocidib SCHEMBL3652 | 0.99 | CDK2 (1.00) | CDK2CDK4CDK1CDK9CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024229271-A1 | NANOPARTICLE-BASED THERANOSTIC PLATFORM FOR DIAGNOSIS AND TREATMENT OF SENESCENCE-RELATED PATHOLOGIES | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2024-11-07 | — | — | WO | claimed |
| CN-117982498-A | Composition containing protein degradation agent or inhibitor and application thereof | 苏州开拓药业股份有限公司 | 2024-05-07 | — | — | CN | claimed |
| US-20160046672-A1 | STAPLING eIF4E INTERACTING PEPTIDES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-02-18 | — | — | US | claimed |
| EP-2925859-A1 | MATURATION OF HEPATOCYTE-LIKE CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS | Takara Bio Europe AB (SE) | 2015-10-07 | — | — | EP | claimed |
| US-20150246946-A1 | PEPTIDES AND METHODS FOR TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-09-03 | — | — | US | claimed |
| WO-2014083132-A1 | MATURATION OF HEPATOCYTE-LIKE CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS | CELLECTIS SA (FR) | 2014-06-05 | — | — | WO | claimed |
| US-12617779-B2 | Self degradation-type CDK9 inhibitor prodrug and liposome encapsulating same | Sumitomo Pharma Co., Ltd. (JP) | 2026-05-05 | — | — | US | disclosed |
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| US-20250332145-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | Piramal Enterprises Limited (IN) | 2025-10-30 | — | — | US | disclosed |
| EP-3890749-B1 | CDK9 INHIBITORS AND POLYMORPHS THEREOF FOR USE AS AGENTS FOR TREATMENT OF CANCER | SUMITOMO PHARMA AMERICA INC (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12447152-B2 | Pharmaceutical combination of PRMT5 inhibitors | LUPIN LIMITED (IN) | 2025-10-21 | — | — | US | disclosed |
| US-12383529-B2 | Pharmaceutical combination for the treatment of cancer | Piramal Enterprises Limited (IN) | 2025-08-12 | — | — | US | disclosed |
| US-12338261-B2 | Alvocidib prodrugs having increased bioavailability | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20150246946-A1 | PEPTIDES AND METHODS FOR TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-09-03 | — | — | US | disclosed |
| US-20150111761-A1 | SUPER-ENHANCERS AND METHODS OF USE THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH | 2015-04-23 | — | — | US | disclosed |
| US-20140296218-A1 | SUPER-ENHANCERS AND METHODS OF USE THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2014-10-02 | — | — | US | disclosed |
| WO-2014149001-A1 | STAPLING eIF4E INTERACTING PEPTIDES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-09-25 | — | — | WO | disclosed |
| US-20140287932-A1 | SUPER-ENHANCERS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-09-25 | — | — | US | disclosed |
| WO-2014083132-A1 | MATURATION OF HEPATOCYTE-LIKE CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS | CELLECTIS SA (FR) | 2014-06-05 | — | — | WO | disclosed |
| US-20130053415-A1 | COMBINATION METHODS FOR TREATMENT OF DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12447152-B2 | Pharmaceutical combination of PRMT5 inhibitors | PRMT5, PRMT1, PRMT6 | CDK2 373/4885CDK4 812/4885CDK1 469/4885 |
| US-12617779-B2 | Self degradation-type CDK9 inhibitor prodrug and liposome encapsulating same | CDK9, CDK6, CDK19 | CDK2 8/4885CDK4 26/4885CDK1 9/4885 |
| US-12338261-B2 | Alvocidib prodrugs having increased bioavailability | CDK1, CDK2, CDK3 | CDK2 2/4885CDK4 4/4885CDK1 1/4885 |
| US-20160046672-A1 | STAPLING eIF4E INTERACTING PEPTIDES | EIF4EBP1, EIF4E, EIF4G2 | CDK2 2158/4885CDK4 2900/4885CDK1 1705/4885 |
| US-20150246946-A1 | PEPTIDES AND METHODS FOR TREATING CANCER | TP53, MDM4, MDM2 | CDK2 207/4885CDK4 9/4885CDK1 178/4885 |
| US-20130053415-A1 | COMBINATION METHODS FOR TREATMENT OF DISEASE | NFATC1, IRF3, BCOR | CDK2 2335/4885CDK4 1075/4885CDK1 2448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.